Compare · Mitochondrial peptide
Humanin vs SS-31
Both are mitochondrial peptide compounds. Here's how they line up on the evidence — graded the same way.
| Humanin | SS-31 | |
|---|---|---|
| Evidence | Animal only | Preliminary human |
| Class | Mitochondrial peptide | Mitochondrial peptide |
| Summary | Humanin is a mitochondrial-derived peptide with interesting cell and animal data in aging and neuroprotection, but the human evidence is entirely observational — no interventional trial of administered humanin in people exists. It's unapproved and effectively uncharacterized for safety in humans. | Elamipretide won a narrow FDA accelerated approval for Barth syndrome in 2025, but its largest trials in myopathy, heart failure, and dry AMD all missed. |
| Full profile → | Full profile → |
Humanin
Humanin is one of the more scientifically intriguing peptides in the "longevity" corner of the gray market: it's the first mitochondrial-derived peptide ever found, it has a plausible cytoprotective mechanism, and its blood levels fall with age. But as of mid-2026, the human evidence that injecting…
SS-31
SS-31, now approved as the drug elamipretide, is one of the more instructive case studies on this site. It is not a gray-market unknown invented by supplement marketers — it is a real molecule that went through real, rigorous clinical trials. The honest lesson is what those trials showed: across…